A panorama of colon cancer in the era of liquid biopsy
Colon cancer (CC) is one of the most frequent cancers worldwide being responsible for over 500 thousand deaths in 2022. Its financial and human burden is expected to increase in the next decades accompanying the growing and aging of the global population. Much of this burden could be alleviated cons...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | The Journal of Liquid Biopsy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950195424000134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846160197706317824 |
|---|---|
| author | Sylvie Devalle Veronica Aran Cesar de Souza Bastos Júnior Vera Lucia Pannain Paulo Brackmann Marcelo Leal Gregório José Eduardo Ferreira Manso Vivaldo Moura Neto |
| author_facet | Sylvie Devalle Veronica Aran Cesar de Souza Bastos Júnior Vera Lucia Pannain Paulo Brackmann Marcelo Leal Gregório José Eduardo Ferreira Manso Vivaldo Moura Neto |
| author_sort | Sylvie Devalle |
| collection | DOAJ |
| description | Colon cancer (CC) is one of the most frequent cancers worldwide being responsible for over 500 thousand deaths in 2022. Its financial and human burden is expected to increase in the next decades accompanying the growing and aging of the global population. Much of this burden could be alleviated considering that the lethality of CC is mostly due to its late diagnosis and failure in the individualized management of patients. Coordinated government actions and implementation of better diagnostic tools capable of detecting CC earlier and of tracking tumoral evolution are mandatory to achieve a reduction in CC's social impact. CtDNA-based liquid biopsy (LB) has great potential to contribute to patients' screening adhesion, CC earlier detection, and to longitudinal tumor follow-up. In this review, we will discuss the latest epidemiological data on CC disease, diagnostic, subtypes, genetics, and treatment management focusing on the advantages and limitations of ctDNA-based LB, including important bottlenecks and solutions necessary for its clinical translation. The latest ctDNA-directed CC clinical trials will also be examined. |
| format | Article |
| id | doaj-art-89d28dfa5f6d4fc9a7bb57f7c97881a2 |
| institution | Kabale University |
| issn | 2950-1954 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Journal of Liquid Biopsy |
| spelling | doaj-art-89d28dfa5f6d4fc9a7bb57f7c97881a22024-11-22T07:41:29ZengElsevierThe Journal of Liquid Biopsy2950-19542024-06-014100148A panorama of colon cancer in the era of liquid biopsySylvie Devalle0Veronica Aran1Cesar de Souza Bastos Júnior2Vera Lucia Pannain3Paulo Brackmann4Marcelo Leal Gregório5José Eduardo Ferreira Manso6Vivaldo Moura Neto7Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria de Estado de Saúde, Rio de Janeiro, Brazil; Corresponding author. Laboratório de Biomedicina do Cérebro, Instituto Estadual do Cérebro Paulo Niemeyer, Rua do Rezende 156, Centro, Rio de Janeiro, 20231-092, Brazil.Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria de Estado de Saúde, Rio de Janeiro, BrazilPoliclínica Naval de Campo Grande, Marinha do Brasil, Rio de Janeiro, BrazilDepartamento de Patologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilClínica de Coloproctologia do Hospital Naval Marcílio Dias - IPB/HNMD, Rio de Janeiro, BrazilInstituto de Pesquisas Biomédicas do Hospital Naval Marcílio Dias - IPB/HNMD, Rio de Janeiro, BrazilDepartamento de Cirurgia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilInstituto Estadual do Cérebro Paulo Niemeyer, Secretaria de Estado de Saúde, Rio de Janeiro, BrazilColon cancer (CC) is one of the most frequent cancers worldwide being responsible for over 500 thousand deaths in 2022. Its financial and human burden is expected to increase in the next decades accompanying the growing and aging of the global population. Much of this burden could be alleviated considering that the lethality of CC is mostly due to its late diagnosis and failure in the individualized management of patients. Coordinated government actions and implementation of better diagnostic tools capable of detecting CC earlier and of tracking tumoral evolution are mandatory to achieve a reduction in CC's social impact. CtDNA-based liquid biopsy (LB) has great potential to contribute to patients' screening adhesion, CC earlier detection, and to longitudinal tumor follow-up. In this review, we will discuss the latest epidemiological data on CC disease, diagnostic, subtypes, genetics, and treatment management focusing on the advantages and limitations of ctDNA-based LB, including important bottlenecks and solutions necessary for its clinical translation. The latest ctDNA-directed CC clinical trials will also be examined.http://www.sciencedirect.com/science/article/pii/S2950195424000134ResistanceManagementAlterationsdPCRNGSMRD |
| spellingShingle | Sylvie Devalle Veronica Aran Cesar de Souza Bastos Júnior Vera Lucia Pannain Paulo Brackmann Marcelo Leal Gregório José Eduardo Ferreira Manso Vivaldo Moura Neto A panorama of colon cancer in the era of liquid biopsy The Journal of Liquid Biopsy Resistance Management Alterations dPCR NGS MRD |
| title | A panorama of colon cancer in the era of liquid biopsy |
| title_full | A panorama of colon cancer in the era of liquid biopsy |
| title_fullStr | A panorama of colon cancer in the era of liquid biopsy |
| title_full_unstemmed | A panorama of colon cancer in the era of liquid biopsy |
| title_short | A panorama of colon cancer in the era of liquid biopsy |
| title_sort | panorama of colon cancer in the era of liquid biopsy |
| topic | Resistance Management Alterations dPCR NGS MRD |
| url | http://www.sciencedirect.com/science/article/pii/S2950195424000134 |
| work_keys_str_mv | AT sylviedevalle apanoramaofcoloncancerintheeraofliquidbiopsy AT veronicaaran apanoramaofcoloncancerintheeraofliquidbiopsy AT cesardesouzabastosjunior apanoramaofcoloncancerintheeraofliquidbiopsy AT veraluciapannain apanoramaofcoloncancerintheeraofliquidbiopsy AT paulobrackmann apanoramaofcoloncancerintheeraofliquidbiopsy AT marcelolealgregorio apanoramaofcoloncancerintheeraofliquidbiopsy AT joseeduardoferreiramanso apanoramaofcoloncancerintheeraofliquidbiopsy AT vivaldomouraneto apanoramaofcoloncancerintheeraofliquidbiopsy AT sylviedevalle panoramaofcoloncancerintheeraofliquidbiopsy AT veronicaaran panoramaofcoloncancerintheeraofliquidbiopsy AT cesardesouzabastosjunior panoramaofcoloncancerintheeraofliquidbiopsy AT veraluciapannain panoramaofcoloncancerintheeraofliquidbiopsy AT paulobrackmann panoramaofcoloncancerintheeraofliquidbiopsy AT marcelolealgregorio panoramaofcoloncancerintheeraofliquidbiopsy AT joseeduardoferreiramanso panoramaofcoloncancerintheeraofliquidbiopsy AT vivaldomouraneto panoramaofcoloncancerintheeraofliquidbiopsy |